**Table S1. Clinicopathologic Features of EGFR-Mutant and ALK-Positive Patients Included in PD-L1 Expression Analysis**

|  |  |  |
| --- | --- | --- |
| Characteristic | EGFR(*N*=68) | ALK(*N*=27) |
| Age at Diagnosis  Median Range | 5839-82 | 5522-78 |
| Sex – no. (%) Male  Female | 22 (32)46 (68) | 13 (48)14 (52) |
| Ethnicity – no. (%)a Caucasian Asian Other | 54 (82)11 (17)1 (2) | 19 (70)7 (26)1 (4) |
| Smoking History – no. (%)b Never  Light (≤10 pack years) Heavy (>10 pack years) | 42 (63)12 (18)13 (19) | 19 (70)5 (19)3 (11) |
| Histology – no. (%) Adenocarcinoma Squamous  | 67 (99)1 (1) | 26 (96)1 (4) |
| Stage at Diagnosis – no. (%) Stage I-II Stage III-IV | 7 (10)61 (90) | 2 (7)25 (93) |
| Current Stage – no. (%) Stage I-II Stage III-IV | 0 (0)68 (100) | 0 (0)27 (100) |

a Not available in 2 patients

b Not available in 1 EGFR pt